Zealand Pharma A/s

Other

Boston Medical Center Corporation

Ulrik Mouritzen

Bjarne Due Larsen

Dongjoon Kim

Sayon Roy

Christiane Voit

Kim Sonne

Peter Glerup

The invention features injection pens for the subcutaneous injection of a peptide and methods of using same.

Injection pen for subcutaneous administration of a peptide

The use of gap junction intercellular communication (GJIC) modulators in the treatment or prevention of diabetic eye disease is disclosed, and more particularly to their use for the treatment or prevention of early stage diabetic retinopathy and diabetic macular edema by inhibiting apoptosis of retinal endothelial cells and inhibiting pericyte loss.

Gap junction intercellular communication modulators and their use for the treatment of diabetic eye disease

Low doses of IL-2 are administered locally and neo-adjuvantly to patients with early stages of the disease. This will result in local high concentrations of IL-2 within the relevant tumor draining lymph nodes. Patients with only early stages of disease will be more responsive to immunotherapy with the expectation of improved survival of patients compared to current therapy standards.

Neoadjuvant treatment of cancer with proleukin

Growing community of inventors

Rungsted Kyst, Denmark

Ulrik Mouritzen